Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL

Blood Cancer J. 2024 Apr 26;14(1):73. doi: 10.1038/s41408-024-01057-z.

Authors

Giuseppe Gritti¹, Silvia Ferrari², Federico Lussana^{2

3}, Anna Maria Barbui², Francesco Landi², Monica Rondi², Alessandro Putelli², Francesco Ballardini², Giulia Quaresmini², Muriel Paganessi², Chiara Pavoni², Arianna Ghirardi⁴, Elisa Gotti⁵, Chiara Capelli⁵, Josée Golay⁴, Martino Introna⁵, Alessandro Rambaldi^{2

3}

Affiliations

¹ Hematology and BMT Unit, ASST Papa Giovanni XXIII, Bergamo, Italy. [email protected].
² Hematology and BMT Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
³ Department of Oncology-Hematology, University of Milan, Milan, Italy.
⁴ Fondazione per la Ricerca Ospedale Maggiore (FROM), Bergamo, Italy.
⁵ Center of Cellular Therapy G. Lanzani, ASST Papa Giovanni XXIII, Bergamo, Italy.

Abstract

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Bispecific* / therapeutic use
Female
Humans
Immune Reconstitution
Immunotherapy, Adoptive / adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Male
Middle Aged
T-Lymphocytes / immunology

Substances

Antibodies, Bispecific
blinatumomab

Grants and funding